Harvett,Despite the FDA encumberance, SBN's primary aim is to...

Harvett,

Despite the FDA encumberance, SBN's primary aim is to grow its sales organically in the US. It is doing this.The main hurdle for SBN atm without FDA clearance is in the workplace, a very big market indeed in the US. It is my understanding that whilst urine testing is entrenched in the US workplace ethos for those reasons expanded upon in the update released yesterday, there is a significant number of large companies (as well as SME's)that do more than 50,000 urine tests per annum that have indicated that they would consider moving to the more cost efficient and less invasive process of saliva testing if-:

a) the efficacy of such a process could be established beyond question and

b) FDA (510)k clearance could be attained for devices used in the saliva testing process

One of the biggest hurdles for any saliva based testing device gaining FDA accreditation atm is that there are absolutely no predicated devices for comparison of test data and efficacy rates. The only process close is urine testing.

I am saying all this because it would seem to me that until we see that quantum shift in the States in respect to saliva based drug testing, it is unlikely that a suitor will try to grab SBN on that basis in the short term. However, a footprint in potentially two of the largest countries in the world , China and Russia make for interesting discussion and strategisation in certain boardrooms of companies that are currently primary players in the drug testing and diagnostic markets.

The name of the game is to generate sales (both oragnically and through JV's), protect the IP at all costs and wait patiently for the wave for it surely will come!


ciao